Meropenem Aptapharma (Meropenem Trihydrate)

Meropenem is a broad‑spectrum carbapenem antibiotic used intravenously to treat severe bacterial infections in various organ systems.

• Complicated intra‑abdominal infections: provides rapid bacterial eradication, reducing infection‑related morbidity and mortality.
• Complicated urinary tract infections: delivers effective bactericidal activity against resistant uropathogens, facilitating clinical cure.
• Nosocomial pneumonia: targets multidrug‑resistant organisms in hospital‑acquired lung infections, improving respiratory outcomes.
• Bacterial meningitis: penetrates the cerebrospinal fluid to eliminate causative pathogens, supporting recovery.
• Severe sepsis and septic shock: delivers broad coverage to control systemic infection and stabilize patient condition.

• Meropenem exerts its bactericidal effect by binding to penicillin‑binding proteins (PBPs) on the bacterial cell wall, inhibiting the final transpeptidation step of peptidoglycan synthesis. This disruption weakens the cell wall, leading to osmotic instability and cell lysis. The drug’s high affinity for a broad range of PBPs contributes to its activity against many Gram‑negative and Gram‑positive organisms, including those resistant to other β‑lactam antibiotics.

Meropenem may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: mild to moderate feeling of sickness often occurring during infusion.
• Diarrhea: loose stools that may develop during treatment.
• Headache: transient cranial discomfort reported by some patients.
• Infusion site reactions: erythema, pain, or phlebitis at the intravenous access point.

Serious or Rare Side Effects

• Seizures: risk increases with high doses or renal impairment.
• Clostridioides difficile‑associated diarrhea: severe colitis requiring prompt medical attention.
• Anaphylaxis or severe hypersensitivity: rapid onset of rash, bronchospasm, or hypotension.

When using Meropenem, clinicians should observe specific safety measures to minimize risks and ensure optimal therapy.

• Renal function monitoring: adjust dosing in patients with impaired kidney clearance.
• CNS disorder caution: avoid or use carefully in individuals with seizure history.
• Hypersensitivity screening: discontinue if signs of allergic reaction appear.
• Concomitant nephrotoxic drugs: evaluate risk when combined with other kidney‑affecting agents.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem can interact with other medicines, altering its efficacy or increasing toxicity; awareness of key interactions guides safe co‑administration.

Major Interactions (Avoid)

• Valproic acid: carbapenems reduce serum valproate levels, risking seizure breakthrough.
• Probenecid: may increase meropenem plasma concentrations, enhancing toxicity risk.

Moderate Interactions (Monitor Closely)

• Loop diuretics: combined use may heighten nephrotoxicity; monitor renal parameters.
• Aminoglycosides: additive renal toxicity potential; assess kidney function regularly.
• Warfarin: may potentiate anticoagulant effect; check INR more frequently.